Evid Based Nurs 7:16 doi:10.1136/ebn.7.1.16
  • Treatment

Oestrogen plus progestogen increased risk of breast cancer in postmenopausal women

 Q In postmenopausal women, does oestrogen plus progestogen hormone therapy increase the risk of abnormal mammographic results and diagnosis of breast cancer?



randomised, placebo controlled trial (Women’s Health Initiative).




blinded (clinicians, participants, data collectors, outcome assessors, and monitoring committee).

GraphicFollow up period:

mean 5.6 years.


40 US clinical centres.


16 608 postmenopausal women who were 50–79 years of age (mean age 63 y). Exclusion criteria: previous hysterectomy, breast cancer, or probable survival <3 years.


1 daily tablet of conjugated equine oestrogen, 0.625 mg, and medroxyprogesterone acetate, 2.5 mg (Prempro, Wyeth Ayerst, Philadelphia, PA, USA) (n = 8506) or placebo (n = 8102).


incidence of breast cancer (total, invasive, and in situ) and …

No Related Web Pages

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article